Clinical trial technology provider Clario and personal electrocardiogram (ECG) technology provider AliveCor have expanded their collaboration to enable ECG readings to be collected from trial participant's homes. Through the expanded collaboration, Clario trial participants will be able to collect medical-grade six-lead ECG readings via AliveCor's devices and app, KardiaRx.

AliveCor enables the collection of ECG readings through its range of FDA-approved devices under the brand name “KardiaMobile.” The devices allow the detection of several cardiac conditions, including atrial fibrillation, bradycardia, tachycardia, and various Sinus Rhythms. KardiaMobile devices are paired with an AI-enabled platform that helps healthcare providers and trial operators track, manage, and monitor patient conditions remotely while enabling data protection through HIPAA-compliant practices.